Black Diamond Therapeutics, Inc.
BDTX
$3.05
$0.113.74%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | 70.00M | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | 70.00M | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | 70.00M | -- | -- | -- |
SG&A Expenses | 4.10M | 4.96M | 3.03M | 5.22M | 9.57M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 13.42M | 15.47M | 15.33M | 18.13M | 22.13M |
Operating Income | -13.42M | 54.53M | -15.33M | -18.13M | -22.13M |
Income Before Tax | -10.56M | 56.54M | -15.99M | -15.56M | -19.91M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -10.56M | 56.54M | -15.99M | -15.56M | -19.91M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -10.56M | 56.54M | -15.99M | -15.56M | -19.91M |
EBIT | -13.42M | 54.53M | -15.33M | -18.13M | -22.13M |
EBITDA | -13.33M | 54.62M | -15.25M | -18.04M | -22.04M |
EPS Basic | -0.19 | 1.00 | -0.28 | -0.28 | -0.36 |
Normalized Basic EPS | -0.12 | 0.62 | -0.15 | -0.17 | -0.23 |
EPS Diluted | -0.19 | 0.98 | -0.28 | -0.28 | -0.36 |
Normalized Diluted EPS | -0.12 | 0.61 | -0.15 | -0.17 | -0.23 |
Average Basic Shares Outstanding | 56.80M | 56.66M | 56.61M | 56.51M | 55.16M |
Average Diluted Shares Outstanding | 56.80M | 57.67M | 56.61M | 56.51M | 55.16M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |